© 2004 New England Journal of Medicine
Current and emerging Alzheimer Disease treatment options hinge on the hypothesis that amyloid β (Aβ), created by the sequential cleavage of amyloid precursor protein (APP), is the culprit behind neurodegeneration and associated cognitive and behavioral abnormalities. This could occur through multiple pathways. (Reprinted with permission from
Neuroscience has made impressive strides since 1936 Nobel laureates Henry Hallett Dale and Otto Loewi first showed that chemicals transmit signals between nerve cells. Yet decades later, scientists have only begun to tap potential therapeutic treatments that target brain and nervous system disorders.
Enormous demand exists for medicines, vaccines, and devices that not only alleviate neurological or psychiatric symptoms, as many current treatments do, but also stem the progression of these debilitating conditions. Statistics from the World Health Organization underscore the unmet need: As many as 50 million people worldwide have ...
